Daraxonrasib Doubles OS for PDAC in Phase III Trial - PubMed
3 hours ago
- #Clinical Trial
- #Pancreatic Cancer
- #Targeted Therapy
- Daraxonrasib, a pan-RAS inhibitor, doubled overall survival compared to chemotherapy in a phase III trial for pancreatic ductal adenocarcinoma (PDAC).
- The results were presented at the American Society of Clinical Oncology Annual Meeting, establishing the drug as a new standard-of-care for second-line metastatic PDAC treatment.
- The findings encourage further trials of RAS-targeted therapies for pancreatic cancer.